4D Molecular Therapeutics' gene therapy cuts Eylea use in wet AMD patients, biotech divulges plans for pivotal studies
4D Molecular Therapeutics said people with wet age-related macular degeneration (AMD) who received the company’s gene therapy as part of a clinical trial needed fewer injections of Eylea, a staple treatment for the eye disease.
In the Phase II PRISM study, 51 patients with wet AMD received either 4D’s gene therapy or their usual injections of Eylea, a blockbuster medicine marketed by Regeneron. Over 24 weeks, 63% of the patients who received a high dose of the gene therapy, dubbed 4D-150, and 50% of those who received the low dose did not need supplemental Eylea injections.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.